Investment analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Merus in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst A.

RECAP: Asian equities paused yesterday after a week of decent gains led by the return of risk-on sentiment in China, ...

Cystic-fibrosis-focused Sionna Therapeutics made its public debut this week, with an upsized public offering. Meanwhile, Titan America had a ...

BofA has initiated coverage of Candel Therapeutics (CADL) with a buy rating, citing the potential of its immunotherapy drug candidates CAN-2409 and CAN-3110. Read more here.

Citi has downgraded Nike Inc.’s stock to neutral from buy, citing the challenges facing the sneaker maker as it attempts to get back on track.

Cytokinetics (CYTK) was initiated by Citi analysts with a Buy rating, citing potential FDA approval for its lead asset aficamten. Read more here.

After more than a decade of planning, a 4.5-mile portion of U.S. Highway 212’s four-lane expansion has begun.Stretching from Cologne (Highway 36) to Carver (Highway 11/Jonathan Carver ...

Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, ...

Pagaya Technologies (NASDAQ:PGY) stock surged 11% in Friday premarket trading after Citi upgraded the AI-powered lending software company to Buy from Neutral as the markdowns on some 2023 loans become ...